Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05187832 · ClinicalTrials.gov registry record · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
A Phase 1 study of Advanced or Metastatic Breast Cancer, sponsored by Kind Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT05187832 is a Phase 1 study of Advanced or Metastatic Breast Cancer that is actively recruiting participants, run by Kind Pharmaceuticals. The registered enrollment target is 61 participants, below the 404-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05187832, a Phase 1 study of Advanced or Metastatic Breast Cancer, is actively recruiting participants, sponsored by Kind Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.
Conditions Studied
Interventions
- DRUG AND019 PO QD
Study Locations (1)
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05187832
The ClinicalTrials.gov registry entry for NCT05187832 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 404-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Kind Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AND019 PO QD is the first listed.
NCT05187832 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05187832 about?
NCT05187832 is a clinical study titled "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer". This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal g...
What is the current status of trial NCT05187832?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-10-05. Estimated completion is 2026-11.
What conditions does trial NCT05187832 study?
This clinical trial studies the following conditions: Advanced or Metastatic Breast Cancer.
What interventions are being tested in trial NCT05187832?
The interventions under investigation include: AND019 PO QD (DRUG).
Who is sponsoring clinical trial NCT05187832?
This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05187832 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
COMPLETED · Phase 1
-
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.